Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
暂无分享,去创建一个
Susan O'Brien | Koji Sasaki | Naveen Pemmaraju | Jorge Cortes | Guillermo Garcia-Manero | Gautam Borthakur | Marina Konopleva | M. Konopleva | Z. Estrov | H. Kantarjian | G. Garcia-Manero | J. Cortes | S. Verstovsek | K. Patel | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | S. O'brien | J. Burger | N. Pemmaraju | J. Jorgensen | Xuemei Wang | Sa A. Wang | A. Ferrajoli | Hagop Kantarjian | Elias Jabbour | Farhad Ravandi | Naval Daver | Jeffrey L Jorgensen | Srdan Verstovsek | Zeev Estrov | Alessandra Ferrajoli | Jan Burger | Courtney D DiNardo | Tapan M Kadia | Christopher B Benton | Xuemei Wang | Keyur Patel | Sa Wang | Sherry Pierce | Carla Tuttle | S. Pierce | K. Sasaki | C. Benton | Carla Tuttle
[1] R. Collins,et al. Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.
[2] A. Letai,et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.
[3] P. Vyas,et al. Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) , 2017 .
[4] J. Jorgensen,et al. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? , 2017, Clinics in laboratory medicine.
[5] Anthony Stein,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[6] M. Konopleva,et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. , 2017, Blood advances.
[7] C. Bloomfield,et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.
[8] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[9] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[10] R. Greil,et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.
[11] M. Konopleva,et al. Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia , 2015, Cancer.
[12] H. Dombret,et al. Azacitidine in untreated acute myeloid leukemia: A report on 149 patients , 2014, American journal of hematology.
[13] H. Kantarjian,et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.
[14] E. Estey,et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson , 2014, Leukemia.
[15] A. Hagemeijer,et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] H. Kantarjian,et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. , 2012, Blood.
[17] M. Minden,et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] W. Jędrzejczak,et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] K. Döhner,et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy , 2012, Haematologica.
[20] A. Levis,et al. Azacitidine for the treatment of patients with acute myeloid leukemia , 2012, Cancer.
[21] D. Niederwieser,et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study , 2012, Leukemia & lymphoma.
[22] H. Kantarjian,et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. , 2010, Blood.
[23] Mark Brandt,et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Dipersio,et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] H. Dombret,et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Bennett,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[27] J. Phillips,et al. Cladribine: not just another purine analogue? , 2009, Expert opinion on investigational drugs.
[28] Sören Lehmann,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.
[29] L. Medeiros,et al. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. , 2006, American journal of clinical pathology.
[30] Susan O'Brien,et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.
[31] Peter F Thall,et al. Monitoring event times in early phase clinical trials: some practical issues , 2005, Clinical trials.
[32] E. Estey,et al. Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome. , 2005 .
[33] W. Jędrzejczak,et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study , 2004, Leukemia.
[34] D. Wyczechowska,et al. The effects of cladribine and fludarabine on DNA methylation in K562 cells. , 2003, Biochemical pharmacology.
[35] E. Estey,et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. , 1996, Leukemia.
[36] E. Estey,et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. , 1996, Blood.
[37] P. Thall,et al. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.
[38] M. Schell,et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[40] G. Beeson,et al. in adults with , 2019 .